22 news items
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
AZZ
CCL
DOCS
20 May 24
. (NYSE:NCLH) gained 7.8% to $16.99 after the company announced 2026 financial targets and raised its 2024 guidance
Oppenheimer Maintains Outperform on Sutro Biopharma, Maintains $10 Price Target
STRO
15 May 24
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $8 Price Target
STRO
14 May 24
Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $8 price target.
HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target
STRO
14 May 24
HC Wainwright & Co. analyst Andrew Fein reiterates Sutro Biopharma (NASDAQ:STRO) with a Buy and maintains $12 price target.
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
STRO
13 May 24
Milestones Luveltamab Tazevibulin (luvelta), FolRα-Targeting ADC Franchise
9qjpqpzem1zg61egf0h0udysojzaiqjm80xm8skdp4 1on2gb36poc
STRO
8 May 24
Insights from analysts' 12-month price targets are revealed, presenting an average target of $12.5, a high estimate
jb3d2r0sd7uip p19df5elx8jsd3q8rlxoakswd66ax5kiwjonqtwg7h
STRO
8 May 24
B of A Securities analyst Tazeen Ahmad initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces Price Target of $12.
hkc51t o9a1dr2un
STRO
3 Apr 24
Piper Sandler analyst Edward Tenthoff reiterates Sutro Biopharma (NASDAQ:STRO) with a Overweight and lowers the price target from $12 to $11.
czszphx8efjvsbq08qp3bo5yvdsyb10
STRO
3 Apr 24
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.
wszq7ohb03xzrv2qsp5j 440ha
STRO
3 Apr 24
Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price target from $25 to $18.
x9cor3d4kxn706s2gs06kn3
STRO
3 Apr 24
JMP Securities analyst Reni Benjamin reiterates Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and maintains $17 price target.
5q8tnu0p32aa4jpjr51bshbcbe0aq62ab938f8gptwct3e
STRO
2 Apr 24
, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline
uovxcngv1i6xil7aigv57shl7v2
STRO
2 Apr 24
stages of pre-clinical development
STRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC) target
STRO-003 has
znwf87q0rgkbgesmooayerrq7lzgseenf
STRO
2 Apr 24
the final stages of pre-clinical developmentSTRO-003 targets ROR1
dcu0ndb8ahllfq0onrf9lfbf6r21b53im
ABTS
AKAN
ALLG
28 Mar 24
a $10 price target.
Kintara Therapeutics, Inc
felnvm64brnulwcrs5mvodgkst4ahty5q4
STRO
28 Mar 24
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.
6pe7n3 hmxh
STRO
27 Mar 24
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target
st1gglxx3 he5u
STRO
27 Mar 24
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.
knv6pdhc1qrj2zt0x05bru6upzdhatqs7uakaavocq
STRO
26 Mar 24
Wedbush analyst David Nierengarten maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and lowers the price target from $12 to $8.
za3oo7a1rx362u7ky6axahhzonc
STRO
26 Mar 24
JMP Securities analyst Reni Benjamin reiterates Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and maintains $17 price target.